FeesSafety
Pluang+

Eloxx doses first patients in Phase 2b trial for rare kidney disease, expects data by mid-2027.

Company Fundamentals
16 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Eloxx doses first patients in Phase 2b trial for rare kidney disease, expects data by mid-2027.

Eloxx Pharmaceuticals has dosed the first two patients in its global Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome, with topline data expected by mid-2027. The company also finalized the protocol and received FDA clearance for a Phase 2 EXPRESS study in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD), aiming to dose the first patient in Q3 2027. Eloxx expanded its leadership team and reported a net loss of $5.5 million for Q3 2026, with $56.3 million in cash to fund operations into 2028. These developments mark significant progress in Eloxx's efforts to develop treatments for rare kidney diseases.

Eloxx Pharmaceuticals' Q3 2026 financial results and business update provide context for readers. As of Nov 16, 2026 18:12 WIB, among 150 priced Health-sector US stocks tradable on Pluang, 66 rose and 50 fell today. Notable movers include Guardant Health Inc. (GH) at USD 147.01 with a 3.18% decline, Humana Inc (HUM) at USD 463.97 gaining 3.10%, and Tango Therapeutics Inc. (TNGX) at USD 24.75 down 2.94%.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
20 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
20 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
20 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App